Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 8: 1051 - 1055

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.08.009

Clinical research

Analysis of prognostic factors of radiotherapy in children with Ⅲ-Ⅳ neuroblastoma

  • Jun-jun ZHOU ,
  • Jie ZHAO ,
  • Jing-yan TANG ,
  • Ma-wei JIANG ,
  • Xiu-mei MA ,
  • Yong-rui BAI
Expand
  • 1.Department of Radiation Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    3.Department of Radiation Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
BAI Yong-rui, E-mail: baiyongruiz@163.com.

Online published: 2021-08-13

Supported by

Science and Technology Innovation Project of Shanghai Science and Technology Commission(17411950403)

Fold

Abstract

Objective

·To analyze the factors affecting the survival and prognosis of the children with medium-, high-, and very high-risk neuroblastoma (NB) in stage Ⅲ?Ⅳ after radiation therapy.

Methods

·A total of 132 cases of neuroblastoma patients from 2008 to 2018 who received local radiotherapy in the Department of Hematology and Oncology, Shanghai International Children′s Medical Center, Shanghai Jiao Tong University School of Medicine, and the Department of Radiation Oncology, Renji Hospital and Xinhua Hospital were included. Treatment options included chemotherapy, surgery, autologous bone marrow transplantation (ABMT), radiotherapy, and later 13-cis-RA maintenance therapy. SPSS 19.0 software was used for the calculation of event-free survival (EFS) and overall survival (OS) rates, as well as univariate and multivariate survival analysis.

Results

·By the end of the follow-up, the EFS rates for the all patients were 87.41% in 1 year, 55.25% in 2 years, 45.02% in 3 years, and 38.67% in 5 years, and the OS rates were 96.02% in 1 year, 83.54% in 2 years, 72.15% in 3 years, and 57.79% in 5 years, respectively. The medium follow-up time was 40.3 months. Univariate survival analysis suggested that the staging, risk grouping, brain metastasis or not, blood lactic acid dehydrogenase and serum ferritin levels were associated with EFS and OS (P<0.05). The presence or absence of bone marrow infiltration was a related factor of EFS (P=0.007), but not OS-related. Factors such as the child′s gender, whether the child was treated with ABMT, the amplification of MYCN proto-oncogene, and the presence of liver metastasis had no significant correlation with EFS or OS. Multivariate survival concluded that brain metastasis was an independent prognosis factor for EFS and OS.

Conclusion

·The amplification of MYCN gene and ABMT treatment may not significantly affect the radiotherapy efficacy and overall survival of stage Ⅲ?Ⅳ NB children. However, the presence of brain metastasis is an independent prognostic factor related to survival and disease progression after radiotherapy.

Key words： neuroblastoma (NB); radiotherapy; prognostic factor; brain metastasis

Cite this article

Jun-jun ZHOU , Jie ZHAO , Jing-yan TANG , Ma-wei JIANG , Xiu-mei MA , Yong-rui BAI . Analysis of prognostic factors of radiotherapy in children with Ⅲ-Ⅳ neuroblastoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(8) : 1051 -1055 . DOI: 10.3969/j.issn.1674-8115.2021.08.009

References

1 MacFarland S, Bagatell R. Advances in neuroblastoma therapy[J]. Curr Opin Pediatr, 2019, 31(1): 14-20.
2 Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study[J]. Int J Radiat Oncol Biol Phys, 2003, 56(1): 28-39.
3 Valteau-Couanet D, Michon J, Boneu A, et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol[J]. J Clin Oncol, 2005, 23(3): 532-540.
4 Liu KX, Naranjo A, Zhang FF, et al. Prospective evaluation of radiation dose escalation in patients with high-risk neuroblastoma and gross residual disease after surgery: a report from the children′s oncology group ANBL0532 study[J]. J Clin Oncol, 2020, 38(24): 2741-2752.
5 Arumugam S, Manning-Cork NJ, Gains JE, et al. The evidence for external beam radiotherapy in high-risk neuroblastoma of childhood: a systematic review[J]. Clin Oncol (R Coll Radiol), 2019, 31(3): 182-190.
6 Matthay KK, Haas-Kogan D, Constine LS. Neuroblastoma[M]//Halperin EC, Constien LS, Tarbell NJ, et al. Pediatric radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2011: 108-136.
7 Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification[J]. J Clin Oncol, 2006, 24(31): 5070-5078.
8 Canete A, Gerrard M, Rubie H, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience[J]. J Clin Oncol, 2009, 27(7): 1014-1019.
9 de Ioris MA, Crocoli A, Contoli B, et al. Local control in metastatic neuroblastoma in children over 1 year of age[J]. BMC Cancer, 2015, 15: 79.
10 范洪君, 黄程, 苏雁, 等. 伴骨髓转移的高危神经母细胞瘤患儿临床特征及预后分析[J]. 中华儿科杂志, 2019, 57(11): 863-869.
Options
Outlines

/

〈 〉